EVALUATION OF THE CLINICAL STAGE FXR AGONIST FXR314 IN HUMAN PRIMARY CELL 3D MODELS OF CROHN’S DISEASE AND ULCERATIVE COLITIS

Aye Mon,Sherwin Gervacio,Haylee Aidnik,Samantha Oxford,Caridad Rosette,Fabrice Piu
DOI: https://doi.org/10.1093/ibd/izae020.121
2024-01-25
Inflammatory Bowel Diseases
Abstract:Abstract There is a critical need for novel approaches to treat inflammatory bowel disease (IBD) that extend beyond modulating the immune response. These innovative strategies should also focus on enhancing the integrity of the intestinal barrier and addressing fibrotic tissue development throughout the course of the disease, both critical components of IBD, to improve long term outcomes. Targeting the ligand-activated nuclear Farnesoid X Receptor (FXR) represents such an emerging opportunity. Intestinal epithelial cells exhibit high expression of FXR which is pivotal for intestinal function by regulating the innate immune response, reducing bacterial translocation into the intestinal wall, preserving the integrity of the epithelial barrier, and potentially reducing fibrotic deposition. We have developed a human 3D co-culture model of multiple cell types derived from Crohn’s disease (CD) or ulcerative colitis patients (UC). These 3D-culture CD and UC models faithfully replicate various aspects of the IBD disease state, including differences in gene expression patterns relative to intestinal tissues from healthy donors, compromised epithelial barrier integrity (as measured by Fluorescein isothiocyanate-dextran and TEER assays) and disrupted fibrotic deposition (as determined via fibrosis biomarkers and quantitative collagen deposition). FXR314 is an orally administered non-bile acid FXR agonist that has completed a Phase 2a clinical trial in NASH and is being considered as a novel therapeutic approach for IBD. We assessed the capacity of FXR314 to improve disease biomarkers in 3D models of human IBD. Specifically, its effects were characterized in five CD donors and three UC donors. Target engagement was demonstrated in all CD and UC donors tested through activation of FGF19, a well-accepted target of FXR activation. In CD donors, FXR314 broadly improved measures of epithelial barrier function in a subset of donors, and fibrotic markers in all five donors. In UC donors, FXR314 improved epithelial barrier function and fibrotic activity in all three donors. As anticipated, the effects seen across the different metrics were concentration dependent. These primary multicellular 3D human IBD models (CD, UC) constitute a powerful tool to more accurately predict the relevance of specific targets and assess the efficacy of therapeutic candidates. Consequently, this could enhance the probability of success when conducting clinical trials. In this study, we demonstrated that the non-bile acid FXR agonist FXR314 improves multiple aspects of Crohn’s disease and ulcerative colitis in human donors, thereby strengthening its potential as a novel therapeutic approach for IBD.
gastroenterology & hepatology
What problem does this paper attempt to address?
The paper mainly explores the following issues: 1. **Effects of AuPhos on Inflammatory Bowel Disease (IBD)**: - Investigated the impact of a novel gold-based compound (AuPhos) on mitochondrial biogenesis, mitochondrial complexes, and antioxidant enzyme levels in human inflammatory bowel disease (IBD) tissues. - Results showed that AuPhos could increase mitochondrial mass and elevate protein levels associated with mitochondrial biogenesis (such as PGC1α, NRF2, and TFAM). Additionally, AuPhos increased the expression of downstream antioxidant markers (such as MnSOD, GPX4, Trx2, and catalase). - AuPhos significantly upregulated the mRNA and protein levels of mitochondrial complexes (mtCO1, mtCO2, Cox6A1, ATP5A1) and antioxidant enzymes (MnSOD, GPX, PRDX-2, -4, -6). - These changes reduced the levels of cytokines and chemokines (IL1β, MCP1, RankL, TNFα) in the tissues, indicating that enhanced mitochondrial function can improve tissue inflammation. - The conclusion suggests that AuPhos has potential therapeutic value in treating IBD by restoring mitochondrial biogenesis. 2. **Mitochondrial Dysfunction in Chronic Pouchitis**: - Explored the relationship between chronic pouchitis and mitochondrial dysfunction in patients undergoing ileal pouch-anal anastomosis (IPAA). - Found that the transcription levels of mitochondrial biogenesis genes (PGC1α, TFAM, NRF1) were significantly reduced in active pouchitis tissues. - In contrast, the reduction of these genes was more pronounced in the ileitis tissues of Crohn's disease (CD) patients. - At the protein level, the expression of NDUFB6 and MTCO1 was significantly reduced in chronic pouchitis tissues. - The conclusion suggests that mitochondrial dysfunction may play a crucial role in the pathogenesis of chronic pouchitis in patients post-IPAA surgery and proposes that mitochondrial-targeted therapies may be effective for refractory pouchitis. 3. **Role of Farnesoid X Receptor (FXR) Agonist FXR314 in IBD**: - Investigated the effects of a non-bile acid FXR agonist FXR314 in a human 3D co-culture model. - In 3D models derived from Crohn's disease (CD) and ulcerative colitis (UC) patients, FXR314 demonstrated its target binding ability by activating FGF19. - In CD and UC models, FXR314 improved epithelial barrier function and fibrosis markers. - Results indicate that FXR314 improves various aspects of Crohn's disease and ulcerative colitis, supporting its potential as a novel IBD treatment. 4. **Colitis Induced by Immune Checkpoint Blockade (ICB)**: - Explored the role of CD4 T cells in colitis induced by immune checkpoint blockade (ICB) therapy. - Evidence suggests a dysregulated intestinal CD4 T cell response in patients with ICB-induced colitis. - Granzyme A-producing CD4 T cells may be one of the main drivers of ICB-induced colitis. These studies provide important insights into the role of mitochondrial dysfunction in IBD and offer clues for developing new therapeutic approaches.